一分钟看懂
这是一项关于尿路上皮癌的III 期研究，登记的药物或干预包括Biospecimen Collection；Bone Scan；Computed Tomography；Docetaxel；Eribulin Mesylate；Gemcitabine Hydrochloride；Magnetic Resonance Imaging；Paclit，当前状态为研究进行中，已停止招募。登记地点显示中国Kingman、Phoenix、Fort Smith、Hot Springs等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；Bone Scan；Computed Tomography；Docetaxel；Eribulin Mesylate；Gemcitabine Hydrochloride；Magnetic Resonance Imaging；Paclitaxel；Sacituzumab Govitecan · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Kingman Regional Medical Center · Kingman
- Cancer Center at Saint Joseph's · Phoenix
- Mercy Hospital Fort Smith · Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs · Hot Springs
- Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande
- PCR Oncology · Arroyo Grande
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine
- Keck Medicine of USC Koreatown · Los Angeles
- Los Angeles General Medical Center · Los Angeles
- USC / Norris Comprehensive Cancer Center · Los Angeles
- Fremont - Rideout Cancer Center · Marysville
- USC Norris Oncology/Hematology-Newport Beach · Newport Beach
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange
- Keck Medical Center of USC Pasadena · Pasadena
- University of California Davis Comprehensive Cancer Center · Sacramento
- Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo
- Mission Hope Medical Oncology - Santa Maria · Santa Maria
- UCHealth University of Colorado Hospital · Aurora
- Penrose-Saint Francis Healthcare · Colorado Springs
- Rocky Mountain Cancer Centers-Penrose · Colorado Springs
- UCHealth - Cherry Creek · Denver
- AdventHealth Porter · Denver
- CommonSpirit Cancer Center Mercy · Durango
- Mercy Medical Center · Durango
- Poudre Valley Hospital · Fort Collins
- Cancer Care and Hematology-Fort Collins · Fort Collins
- UCHealth Greeley Hospital · Greeley
- UCHealth Highlands Ranch Hospital · Highlands Ranch
- CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood
- AdventHealth Littleton · Littleton
公开的入选条件
- * Participant must have predominant histologically or cytologically proven urothelial carcinoma in a metastatic site
- * Participant must have evidence of metastatic urothelial carcinoma based on CT or MRI within 28 days prior to registration
- * Participant must have had progression of disease following prior therapy at the discretion of the treating investigator
- * Participants must not require immediate central nervous system (CNS)-specific treatment, in the opinion of the treating investigator if they have active brain metastases (defined as new or progressive brain metastases) or leptomeningeal disease
- * Participant must have had prior systemic therapy in metastatic setting that:
- Included enfortumab vedotin
- Included a PD1/PDL1 antibody
- NOTE: Under the discretion of the treating physician, participants who are not candidates for PD1/PDL1 antibody systemic therapy are allowed
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04579224；登记信息更新于 2026-09-16。